ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1793

Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis

Debbie M. Roeleveld1, Loreto Parga Vidal2, Monique M. Helsen2, Birgitte Walgreen3, Bianka Marklein4, Karl Skriner5, Martin Hegen6, Peter L. van Lent2, Fons A.J. van de Loo2, Wim B. van den Berg2, Peter M. van der Kraan2 and Marije I. Koenders2, 1Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Experimental, Radboud university medical center, Nijmegen, Netherlands, 4Humboldt University and Free University, Berlin, Germany, 5Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 6Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: adaptive immunity, Animal models, cytokines, inflammatory cytokines and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with disease activity markers and more erosive disease. The role of IL-22 in autoimmunity and inflammation appears to be greatly contradictory, being both pro- and anti-inflammatory. Previous work in other disease models suggested that the presence of IL-17 determines the inflammatory effect of IL-22, being protective in the absence and pathogenic in the presence of IL-17. The purpose of our study was to further unravel the role of IL-22 during experimental arthritis, in particular focusing on the cytokine interactions within the inflammatory environment.

Methods: To investigate the potential of IL-22 to drive joint inflammation and destruction, IL-22 was overexpressed in murine knee joints using an adenoviral construct (AdIL-22), and synovial biopsies and whole joints were collected for mRNA/protein expression analysis and histological scoring of joint pathology. To study the interaction of IL-22 within the disease cytokine network, AdIL-22 was injected intra-articularly as single cytokine, or combined with a second vector overexpressing TNFα, IL-17 or IL-1β. Furthermore, we studied the effect of local IL-22 overexpression on two experimental arthritis models: SCW and K/BxN serum transfer arthritis. Our second strategy involved using IL-22-deficient mice, which were crossed with IL-1Ra-deficient mice that spontaneously develop T cell-driven arthritis. Besides the effect of IL-22-deficiency on arthritis incidence and severity, we also investigated how the lack of IL-22 signaling affected the responsiveness to anti-IL-17 therapy in this IL-17-driven model.

Results: Despite the significantly enhanced synovial mRNA expression of pro-inflammatory and pro-destructive genes like IL-6, KC, S100A8 and RANKL, surprisingly IL-22-overexpression did not result in any sign of joint pathology in the knee joints of naïve mice. Furthermore, IL-22 neither aggravated disease severity during both models of innate immune-driven experimental arthritis, nor did it affect IL-17-, IL-1β-, or TNFα-induced joint inflammation when overexpressed in combination with other cytokines. Interestingly, in comparison to the spontaneous arthritis development in classical IL-1Ra-/- mice, the absence of IL-22 significantly reduced disease incidence and severity in this model. While the arthritis incidence in regular IL-1Ra-/- mice reached up to 95% at the age of 15 weeks, IL-22-/- x IL-1Ra-/- mice only showed 50% disease onset. In line with suppressed disease severity, anti-hnRNP autoantibodies were lowered in IL-22-/- x IL-1Ra-/- mice. No effects were observed on T cell responses. Remarkably, in the absence of IL-22 the therapeutic efficacy of anti-IL-17 treatment on arthritis progression in these mice was lost.

Conclusion: This study not only confirms the pro-inflammatory role of IL-22 in the development and progression of experimental arthritis, it also demonstrates a novel role in the formation of anti-hnRNP antibodies. Finally, we demonstrated that IL-17 is not a determinant for the pro- or anti-inflammatory character of IL-22 in experimental arthritis.


Disclosure: D. M. Roeleveld, None; L. Parga Vidal, None; M. M. Helsen, None; B. Walgreen, None; B. Marklein, None; K. Skriner, None; M. Hegen, Pfizer Inc, 3; P. L. van Lent, None; F. A. J. van de Loo, None; W. B. van den Berg, None; P. M. van der Kraan, None; M. I. Koenders, None.

To cite this abstract in AMA style:

Roeleveld DM, Parga Vidal L, Helsen MM, Walgreen B, Marklein B, Skriner K, Hegen M, van Lent PL, van de Loo FAJ, van den Berg WB, van der Kraan PM, Koenders MI. Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interleukin-17-is-not-a-determinant-for-the-pro-or-anti-inflammatory-character-of-interleukin-22-in-experimental-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-17-is-not-a-determinant-for-the-pro-or-anti-inflammatory-character-of-interleukin-22-in-experimental-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology